TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26889783

Group type: EXPERIMENTAL
Intervention: Virgin Olive Oil enriched with its own phenolic compounds (FVOO)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Virgin Olive Oil complemented with thyme phenolic compounds (FVOOT)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Virgin Olive Oil (VOO)
Number of subjects: 33
Study: 26215196

Group type: EXPERIMENTAL
Intervention: Completion axillary lymph node dissection (ALND)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Completion axillary lymph node dissection (ALND) in T3+ group
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Completion axillary lymph node dissection (ALND) in T1/T2 group
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: ILCs meeting ACOSOG Z0011 criteria
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: ILCs not meeting ACOSOG Z0011 criteria
Number of subjects: 59
Study: 23885519

Group type: EXPERIMENTAL
Intervention: Intrathecal morphine 300 microg (group M, n=20)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intrathecal morphine 300 microg + bupivacaine 2 mg (group MB, n=20)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intrathecal morphine 300 microg + bupivacaine 2 mg + fentanyl 25 microg (group MBF, n=20)
Number of subjects: 60
Study: 21180957

Group type: EXPERIMENTAL
Intervention: 2x/day fluoride dentifrice (FD)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 2x/day fluoride dentifrice (FD) + 1x/day fluoride mouthrinse (FR)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 3x/day fluoride dentifrice (FD)
Number of subjects: 12
Study: 19034875

Group type: EXPERIMENTAL
Intervention: Simvastatin (20 mg/day)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 16845924

Group type: EXPERIMENTAL
Intervention: Neural network algorithms (Standard Backpropagation, Scaled Conjugate Gradient, Backpropagation with Bayesian Regularization)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Backpropagation with Bayesian Regularization (BR)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Feature selection technique with BR
Number of subjects: 24
Study: 14583862

Group type: EXPERIMENTAL
Intervention: Dalbavancin (2 doses: 1100 mg IV once and 500 mg IV one week later)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Dalbavancin (1 dose: 1100 mg IV)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Standard-of-care regimen
Number of subjects: 62
Study: 10881066

Group type: EXPERIMENTAL
Intervention: 750ml of 10% mannitol (Group M)
Number of subjects: 80

Group type: COMPARATOR
Intervention: 180ml of sodium phosphate preparation (Group NaP)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Group NaP (sodium phosphate)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Group M (mannitol)
Number of subjects: 80
Study: 7722124

Group type: EXPERIMENTAL
Intervention: rt‐PA (0.03 mg/kg body weight per h for 3 consecutive days) plus heparin
Number of subjects: 67

Group type: COMPARATOR
Intervention: heparin plus placebo
Number of subjects: 67
Study: 1974506

Group type: EXPERIMENTAL
Intervention: Carvedilol 25 mg once daily (o.d.)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Atenolol 50 mg once daily (o.d.)
Number of subjects: 131
Study: 7030149

Group type: EXPERIMENTAL
Intervention: Epidural anaesthesia
Number of subjects: 12

Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 12
Study: 30587216

Group type: EXPERIMENTAL
Intervention: Reactor™
Number of subjects: 16

Group type: COMPARATOR
Intervention: Standard technique
Number of subjects: 16
Study: 26880615

Group type: EXPERIMENTAL
Intervention: Indomethacin (1.2 mg/kg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: COMPARATOR
Intervention: Ketorolac (0.25 mg/kg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Naproxen (4.2 mg/kg)
Number of subjects: 10
Study: 24716651

Group type: EXPERIMENTAL
Intervention: Computer-assisted surgery
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional surgery
Number of subjects: 20
Study: 23419888

Group type: EXPERIMENTAL
Intervention: Peer-led groups
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Clinician-led groups
Number of subjects: 319

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 319

Group type: COMPARATOR
Intervention: Educational brochure control
Number of subjects: 319
Study: 20627032

Group type: EXPERIMENTAL
Intervention: Ilaprazole 5 mg/d
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Ilaprazole 10 mg/d
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Ilaprazole 20 mg/d
Number of subjects: 42

Group type: COMPARATOR
Intervention: Omeprazole 20 mg/d
Number of subjects: 42
Study: 18256346

Group type: EXPERIMENTAL
Intervention: Exercise (n = 20)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Mental stress (n = 20)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (n = 20)
Number of subjects: 60
Study: 16606388

Group type: EXPERIMENTAL
Intervention: Active-fixation leads (1488T St. Jude and Medtronic 5076)
Number of subjects: 100
Study: 12742556

Group type: EXPERIMENTAL
Intervention: ethinyl estradiol/desogestrel
Number of subjects: 47

Group type: COMPARATOR
Intervention: ethinyl estradiol/levonorgestrel
Number of subjects: 47
Study: 10389774

Group type: EXPERIMENTAL
Intervention: 15 microg of epinephrine IV
Number of subjects: 96

Group type: COMPARATOR
Intervention: 3 mL of saline IV
Number of subjects: 96
Study: 9015519

Group type: EXPERIMENTAL
Intervention: Ivermectin, 400 micrograms/kg, 12 fortnightly doses
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Diethylcarbamazine (DEC), 10 mg/kg, 12 fortnightly doses
Number of subjects: 37

Group type: COMPARATOR
Intervention: Low dose ivermectin (LDIC group)
Number of subjects: 37
Study: 2006699

Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 7039813

Group type: EXPERIMENTAL
Intervention: TAD (thioguanine + Ara‐C + Daunorubin)
Number of subjects: 455

Group type: EXPERIMENTAL
Intervention: DA (Daunorubicin + Ara‐C)
Number of subjects: 455

Group type: EXPERIMENTAL
Intervention: AVML (Arabinosyl Cytosine + vincristine + methotrexate + leucovorin)
Number of subjects: 455

Group type: COMPARATOR
Intervention: DA vs TAD
Number of subjects: 455

Group type: COMPARATOR
Intervention: Maintenance therapy (B/A, BCG, NFT)
Number of subjects: 455

Group type: EXPERIMENTAL
Intervention: BCG (Bacillus Calmette‐Guerin)
Number of subjects: 455
Study: 3902388

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (32 mg once daily)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Number of subjects: 13
Study: 28932882

Group type: EXPERIMENTAL
Intervention: No episiotomy
Number of subjects: 309

Group type: COMPARATOR
Intervention: Standard care (episiotomy)
Number of subjects: 309
Study: 25803759

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided lumbar transforaminal epidural injection
Number of subjects: 80

Group type: COMPARATOR
Intervention: Fluoroscopy-controlled lumbar transforaminal epidural injection
Number of subjects: 80
Study: 24782192

Group type: EXPERIMENTAL
Intervention: Gene expression profiles in peripheral whole blood samples
Number of subjects: 0
Study: 22369601

Group type: EXPERIMENTAL
Intervention: Daily fetal movement counting from pregnancy week 28
Number of subjects: 1013

Group type: COMPARATOR
Intervention: Standard Norwegian antenatal care (control)
Number of subjects: 1013

Group type: EXPERIMENTAL
Intervention: Daily fetal movement counting
Number of subjects: 1013
Study: 20660830

Group type: EXPERIMENTAL
Intervention: Topotecan plus Cyclophosphamide (TOPO/CTX)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Topotecan (TOPO)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Topotecan (TOPO) and Topotecan plus Cyclophosphamide (TOPO/CTX)
Number of subjects: 119
Study: 18413423

Group type: EXPERIMENTAL
Intervention: Low-release ENG implant combined with TU injections (750 mg every 10 or 12 weeks)
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: High-release ENG implant combined with TU injections (1000 mg every 12 weeks)
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: Active treatment groups (ENG implant with TU injections)
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: Active treatment groups
Number of subjects: 354

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 354
Study: 15854634

Group type: EXPERIMENTAL
Intervention: Trilostane (120 mg twice daily for the first 24 h, then 240 mg twice daily for the next 24 h) + misoprostol (low-dose vaginal group: 200 microg every 4 h)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Trilostane + misoprostol (high-dose vaginal group: initial dose of 400 microg followed by 200 microg every 4 h)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Trilostane + misoprostol (vaginal-oral group: 400 microg vaginally followed by 200 microg orally every 4 h)
Number of subjects: 93
Study: 12439845

Group type: EXPERIMENTAL
Intervention: rHuEPO (recombinant human erythropoietin)
Number of subjects: 10
Study: 10529135

Group type: EXPERIMENTAL
Intervention: Beraprost sodium (BPS)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study: 7591314

Group type: EXPERIMENTAL
Intervention: Pre-hospital treatment with anistreplase followed by placebo after hospital admission (pre-hospital group; 2750 patients)
Number of subjects: 5469

Group type: COMPARATOR
Intervention: Placebo followed by anistreplase (hospital group; 2719 patients)
Number of subjects: 5469
Study: 2144914

Group type: EXPERIMENTAL
Intervention: Variable resistance dynamic exercise every other week (1X/2 weeks, n = 19)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Once per week (1X/week, n = 22)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Twice per week (2X/week, n = 23)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Three times per week (3X/week, n = 21)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Isometric training once per week (n = 14)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Control group (no training, n = 15)
Number of subjects: 114
Study: 7031861

Group type: EXPERIMENTAL
Intervention: 400 mg bacampicillin 3 times daily
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: 1200 mg bacampicillin twice daily
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: 400 mg bacampicillin
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: 1200 mg bacampicillin
Number of subjects: 47
Study: 31256644

Group type: EXPERIMENTAL
Intervention: Closed suction drain (CSD)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Sham drain (SCDRN)
Number of subjects: 29
Study: 29787357

Group type: EXPERIMENTAL
Intervention: Prophylactic cranial irradiation (PCI)
Number of subjects: 175

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 175
Study: 26903039

Group type: EXPERIMENTAL
Intervention: TAVR
Number of subjects: 2559
Study: 25122976

Group type: EXPERIMENTAL
Intervention: Oscillating-rotating power toothbrush with angled CrissCross bristles
Number of subjects: 130

Group type: COMPARATOR
Intervention: Sonic toothbrush (Sonicare DiamondClean)
Number of subjects: 130
Study: 22976566

Group type: EXPERIMENTAL
Intervention: Topical ozonated olive oil (OZO) as an adjunct to scaling and root planing (SRP)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Topical ozonated olive oil (OZO) as a monotherapy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Topical chlorhexidine gel as a monotherapy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Scaling and root planing (SRP)
Number of subjects: 20
Study: 20860635

Group type: EXPERIMENTAL
Intervention: Askina Calgitrol Ag(®)
Number of subjects: 65

Group type: COMPARATOR
Intervention: 1% silver sulfadiazine (1% AgSD)
Number of subjects: 65
Study: 17990196

Group type: EXPERIMENTAL
Intervention: EMDR treatment (eight weekly sessions)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Waiting List Control (WLC)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: EMDR treatment
Number of subjects: 33
Study: 15898028

Group type: EXPERIMENTAL
Intervention: Intrathecal sufentanil (7.5 microg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Intravenous sufentanil (7.5 microg)
Number of subjects: 40
Study: 11127247

Group type: EXPERIMENTAL
Intervention: Chloroquine prophylaxis for > or = 8 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Case management
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Iron‐folic acid supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Case management with parasitaemia and haemoglobin levels < 100 g/L
Number of subjects: 0

Group type: COMPARATOR
Intervention: Case management with low haemoglobin level at enrolment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chloroquine prophylaxis
Number of subjects: 0
Study: 9417816

Group type: EXPERIMENTAL
Intervention: High-dose TNF, interferon gamma, and melphalan (TIM) in isolated limb perfusion (ILP)
Number of subjects: 44

Group type: COMPARATOR
Intervention: ILP without TNF/interferon gamma (IFN-gamma)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: TIM-ILP
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: sTNF-RII concentration in excess over circulating TNF
Number of subjects: 44
Study: 8317533

Group type: EXPERIMENTAL
Intervention: Embryo transfer, zygote intrafallopian transfer, and frozen embryo transfer
Number of subjects: 45
Study: 2872822

Group type: EXPERIMENTAL
Intervention: Benztropine (7-day course)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo (7-day course)
Number of subjects: 39
Study: 30045168

Group type: EXPERIMENTAL
Intervention: Cirrhosis patients with CDI
Number of subjects: 12274

Group type: COMPARATOR
Intervention: Non-cirrhosis patients with CDI
Number of subjects: 12274

Group type: EXPERIMENTAL
Intervention: Decompensated cirrhosis patients
Number of subjects: 12274
Study: 28207505

Group type: EXPERIMENTAL
Intervention: EBCA (esomeprazole and colloidal bismuth pectin with clarithromycin and amoxicillin)
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: EBLA (esomeprazole and colloidal bismuth pectin with levofloxacin and amoxicillin)
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: ELA (esomeprazole with levofloxacin and amoxicillin)
Number of subjects: 270
Study: 26025562

Group type: EXPERIMENTAL
Intervention: Buspirone 15 mg with melatonin-SR 3 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Buspirone 15 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 22959634

Group type: EXPERIMENTAL
Intervention: L-arginine infusion
Number of subjects: 8

Group type: COMPARATOR
Intervention: Saline infusion (control)
Number of subjects: 8
Study: 21996389

Group type: EXPERIMENTAL
Intervention: Dopamine-treated graft
Number of subjects: 93
Study: 19220284

Group type: EXPERIMENTAL
Intervention: Bortezomib
Number of subjects: 40
Study: 17028221

Group type: EXPERIMENTAL
Intervention: Vaccine dilution (1:1 or 1:10)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Previous vaccinia virus vaccination status
Number of subjects: 0
Study: 15871456

Group type: EXPERIMENTAL
Intervention: Open-face stainless steel crowns (SSCs)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Veneered stainless steel crowns (SSCs)
Number of subjects: 33
Study: 10721538

Group type: EXPERIMENTAL
Intervention: Antibiotics (specifically amoxycillin as first line treatment)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9305231

Group type: EXPERIMENTAL
Intervention: Mometasone furoate 200 micrograms once daily
Number of subjects: 550

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 200 micrograms once daily
Number of subjects: 550

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 550
Study: 8360362

Group type: EXPERIMENTAL
Intervention: Meridol mouthrinse
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Chlorhexidine mouthrinse
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo mouthrinse
Number of subjects: 36
Study: 3540309

Group type: EXPERIMENTAL
Intervention: Behavioral stress management
Number of subjects: 10

Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 10
Study: 30003808

Group type: EXPERIMENTAL
Intervention: Personal website
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Social Media Index (SMI) above 3
Number of subjects: 116
Study: 30203534

Group type: EXPERIMENTAL
Intervention: Prabotulinumtoxin A (NABOTA®)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Onabotulinumtoxin A (ONA)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 22
Study: 29173604

Group type: EXPERIMENTAL
Intervention: Burst exercise (3 continuous bursts of 12 minutes of high-intensity exercise at 85% of maximal heart rate, 5 days per week for 3 months)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Burst exercise
Number of subjects: 40

Group type: COMPARATOR
Intervention: Moderate-intensity continuous exercise training (MICT) (40 minutes at 60% of maximal heart rate, 5 days per week for 3 months)
Number of subjects: 40
Study: 26361154

Group type: EXPERIMENTAL
Intervention: Top tertiles of Lp(a)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Top tertiles of OxPL-apoB
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Top tertiles of Lp(a) or OxPL-apoB after adjustment
Number of subjects: 220
Study: 24139769

Group type: EXPERIMENTAL
Intervention: Freshplace intervention
Number of subjects: 228

Group type: COMPARATOR
Intervention: Control group (traditional food pantries)
Number of subjects: 228
Study: 20841314

Group type: EXPERIMENTAL
Intervention: Self-etching primer (SEP) (Transbond Plus)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Phosphoric acid (PA) (37% for 30 seconds)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Self-etching primer (SEP)
Number of subjects: 80
Study: 18356656

Group type: EXPERIMENTAL
Intervention: 100 mg of dexamethasone
Number of subjects: 28

Group type: COMPARATOR
Intervention: Sterile saline (control)
Number of subjects: 28
Study: 16554592

Group type: EXPERIMENTAL
Intervention: Intraluminal brachytherapy using iridium-192 with a dose of 14 Gy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group with a dummy source
Number of subjects: 40
Study: 14567808

Group type: EXPERIMENTAL
Intervention: SprayGel
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control (no SprayGel)
Number of subjects: 45
Study: 10730995

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBOT) at 2.5 ATA for 60 min
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo group with normoxic mixture (P(I)O2 = 0.2 ATA)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both groups (HBOT and placebo)
Number of subjects: 24
Study: 8040015

Group type: COMPARATOR
Intervention: Standard radiotherapy covering the whole sphenoid sinus
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Radiotherapy using a modified technique that shields the pituitary and the anterior part of the hypothalamus
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 152
Study: 3057146

Group type: EXPERIMENTAL
Intervention: Nalbuphine
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Fentanyl
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 31394300

Group type: EXPERIMENTAL
Intervention: Adjunctive photodynamic therapy (PDT) with full-mouth disinfection (FMD)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Full-mouth disinfection (FMD) alone
Number of subjects: 30
Study: 28486704

Group type: EXPERIMENTAL
Intervention: 6-month lifestyle intervention programme preceding infertility treatment
Number of subjects: 564

Group type: COMPARATOR
Intervention: Prompt infertility treatment
Number of subjects: 564

Group type: EXPERIMENTAL
Intervention: All live births conceived within 24 months
Number of subjects: 564
Study: 25853229

Group type: EXPERIMENTAL
Intervention: Weekly motivational counseling
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control
Number of subjects: 57
Study: 23169517

Group type: EXPERIMENTAL
Intervention: Cabozantinib (100 mg daily)
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Cabozantinib
Number of subjects: 171

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 171
Study: 21336155

Group type: EXPERIMENTAL
Intervention: travoprost 0.004% once daily
Number of subjects: 30

Group type: COMPARATOR
Intervention: pilocarpine 1% 4 times daily
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: both groups
Number of subjects: 30
Study: 19171726

Group type: EXPERIMENTAL
Intervention: Surgical therapy (gastric banding surgery)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 0
Study: 17521747

Group type: EXPERIMENTAL
Intervention: Subtotal bovie tonsillectomy
Number of subjects: 39

Group type: COMPARATOR
Intervention: Total monopolar tonsillectomy
Number of subjects: 39
Study: 15064584

Group type: EXPERIMENTAL
Intervention: Glycine-arginine-alpha-ketoisocaproic acid (GAKIC) 11.2 g
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (PLC)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: GAKIC
Number of subjects: 10

Group type: COMPARATOR
Intervention: GAKIC and PLC
Number of subjects: 10
Study: 11685491

Group type: EXPERIMENTAL
Intervention: 60 Gy radioiodine dose
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: 90 Gy radioiodine dose
Number of subjects: 58

Group type: COMPARATOR
Intervention: Low-dose therapy (60 Gy)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Low-dose therapy (90 Gy)
Number of subjects: 58
Study: 9555775

Group type: EXPERIMENTAL
Intervention: Palmaz‐Schatz coronary stent
Number of subjects: 407

Group type: COMPARATOR
Intervention: PTCA
Number of subjects: 407
Study: 8526243

Group type: EXPERIMENTAL
Intervention: Fluoxetine, 20 mg/day for 5 weeks
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo for 5 weeks
Number of subjects: 68
Study: 2405792

Group type: EXPERIMENTAL
Intervention: Distal splenorenal shunt (DSRS)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Endoscopic sclerotherapy (ES)
Number of subjects: 40
Study: 511533

Group type: EXPERIMENTAL
Intervention: Clonazepam (Rivotril) 1 mg per day
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Clonazepam (Rivotril) 2 mg per day
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 30670421

Group type: EXPERIMENTAL
Intervention: 100-mg levofloxacin dispersible tablets
Number of subjects: 133

Group type: COMPARATOR
Intervention: Adult (250-mg) levofloxacin tablets
Number of subjects: 133
Study: 28157380

Group type: EXPERIMENTAL
Intervention: Omega-3 supplementation (2g/day)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo (mainly oleic and linoleic acid)
Number of subjects: 95